MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML
Author(s) -
Vegi M. Naidu,
Josef Klappacher,
Franz Oswald,
Medhanie Mulaw,
Amit Mandoli,
Vere. Thiel,
Shiva Bamezai,
Kristin Feder,
Joost H.A. Martens,
Vijay P.S. Rawat,
Tamoghna Mandal,
Leticia QuintanillaMartínez,
Karsten Spiekermann,
Wolfgang Hiddemann,
Konstanze Döhner,
Hartmut Döhner,
Hendrik G. Stunnenberg,
Michaela FeuringBuske,
Christian Buske
Publication year - 2016
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2016.05.094
Subject(s) - myeloid leukemia , cancer research , homeobox , transcription factor , biology , leukemia , druggability , genetics , gene
Homeobox genes are known to be key factors in leukemogenesis. Although the TALE family homeodomain factor Meis1 has been linked to malignancy, a role for MEIS2 is less clear. Here, we demonstrate that MEIS2 is expressed at high levels in patients with AML1-ETO-positive acute myeloid leukemia and that growth of AML1-ETO-positive leukemia depends on MEIS2 expression. In mice, MEIS2 collaborates with AML1-ETO to induce acute myeloid leukemia. MEIS2 binds strongly to the Runt domain of AML1-ETO, indicating a direct interaction between these transcription factors. High expression of MEIS2 impairs repressive DNA binding of AML1-ETO, inducing increased expression of genes such as the druggable proto-oncogene YES1. Collectively, these data describe a pivotal role for MEIS2 in AML1-ETO-induced leukemia.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom